1. Home
  2. SLP vs PRTC Comparison

SLP vs PRTC Comparison

Compare SLP & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Simulations Plus Inc.

SLP

Simulations Plus Inc.

HOLD

Current Price

$19.18

Market Cap

322.4M

Sector

Technology

ML Signal

HOLD

Logo PureTech Health plc

PRTC

PureTech Health plc

HOLD

Current Price

$16.76

Market Cap

386.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLP
PRTC
Founded
1996
2015
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
322.4M
386.7M
IPO Year
1997
N/A

Fundamental Metrics

Financial Performance
Metric
SLP
PRTC
Price
$19.18
$16.76
Analyst Decision
Buy
Analyst Count
7
0
Target Price
$27.25
N/A
AVG Volume (30 Days)
336.7K
2.2K
Earning Date
01-08-2026
08-28-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.20
Revenue
$79,179,000.00
$6,391,000.00
Revenue This Year
$2.02
N/A
Revenue Next Year
$6.92
N/A
P/E Ratio
N/A
$8.13
Revenue Growth
13.09
1265.60
52 Week Low
$12.39
$13.30
52 Week High
$37.67
$20.00

Technical Indicators

Market Signals
Indicator
SLP
PRTC
Relative Strength Index (RSI) 56.71 49.31
Support Level $17.74 $16.75
Resistance Level $19.62 $17.85
Average True Range (ATR) 0.72 0.46
MACD -0.09 0.06
Stochastic Oscillator 53.23 40.48

Price Performance

Historical Comparison
SLP
PRTC

About SLP Simulations Plus Inc.

Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

Share on Social Networks: